• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

CITALOPRAM Drug Record

  • Summary
  • Interactions
  • Claims
  • CITALOPRAM chembl:CHEMBL549 Approved

    Alternate Names:

    CITALOPRAM
    CELEXA

    Drug Info:

    Drug Class antidepressive agents, second-generation
    Year of Approval 1998
    FDA Approval 1998
    Drug Class small molecule
    Drug Indications Antidepressive Agents, Second-Generation
    (3 More Sources)

    Publications:

    Niitsu T et al., 2013, Pharmacogenetics in major depression: a comprehensive meta-analysis., Prog Neuropsychopharmacol Biol Psychiatry
    Arias B et al., 2013, TPH1, MAOA, serotonin receptor 2A and 2C genes in citalopram response: possible effect in melancholic and psychotic depression., Neuropsychobiology
    Illi A et al., 2009, 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression., Neuroreport
    Laje G et al., 2007, Genetic markers of suicidal ideation emerging during citalopram treatment of major depression., Am J Psychiatry
    Sangkuhl K et al., 2011, PharmGKB summary: citalopram pharmacokinetics pathway., Pharmacogenet Genomics
    Serretti A et al., 2011, A preliminary investigation of the influence of CREB1 gene on treatment resistance in major depression., J Affect Disord
    Perlis RH et al., 2007, Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study., Arch Gen Psychiatry
    Rasmussen et al., 2009, A single nucleotide polymorphism in the human serotonin transporter introduces a new site for N-linked glycosylation., Neuropharmacology
    Schloss et al., 1995, Heterogeneity of antidepressant binding sites on the recombinant rat serotonin transporter SERT1., Biochemistry
    Plenge et al., 2005, High- and low-affinity binding of S-citalopram to the human serotonin transporter mutated at 20 putatively important amino acid positions., Neurosci. Lett.
    Dugar et al., 2001, Compensatory responses in the aging hippocampal serotonergic system following neurodegenerative injury with 5,7-dihydroxytryptamine., Synapse
    Bareggi et al., 2007, The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders., Expert Opin Drug Metab Toxicol
    Tatsumi et al., 1997, Pharmacological profile of antidepressants and related compounds at human monoamine transporters., Eur. J. Pharmacol.
    Vicentic et al., 1999, Serotonin transporter production and degradation rates: studies with RTI-76., Brain Res.
    Eriksson et al., 1999, Effects of mCPP on the extracellular concentrations of serotonin and dopamine in rat brain., Neuropsychopharmacology
    Dutta et al., 2001, Structure-activity relationship studies of 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine derivatives and their N-analogues: evaluation of O-and N-analogues and their binding to monoamine transporters., J. Med. Chem.
    Zhong et al., 2009, An allosteric binding site at the human serotonin transporter mediates the inhibition of escitalopram by R-citalopram: kinetic binding studies with the ALI/VFL-SI/TT mutant., Neurosci. Lett.
    Maines et al., 1999, Corticosterone regulation of serotonin transporter and 5-HT1A receptor expression in the aging brain., Synapse
    Coleman JA et al., 2016, X-ray structures and mechanism of the human serotonin transporter., Nature
    Tsai SJ et al., 2008, Plasminogen activator inhibitor-1 gene is associated with major depression and antidepressant treatment response., Pharmacogenet Genomics
    Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
    Arias B et al., 2009, Dysbindin gene (DTNBP1) in major depression: association with clinical response to selective serotonin reuptake inhibitors., Pharmacogenet Genomics
    Yang Z et al., 2012, Association of APC and REEP5 gene polymorphisms with major depression disorder and treatment response to antidepressants in a Han Chinese population., Gen Hosp Psychiatry
    Perroud N et al., 2011, Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample., Pharmacogenomics
    Zou YF et al., 2010, Meta-analysis of FKBP5 gene polymorphisms association with treatment response in patients with mood disorders., Neurosci Lett
    Sarginson JE et al., 2010, FKBP5 polymorphisms and antidepressant response in geriatric depression., Am J Med Genet B Neuropsychiatr Genet
    Kirchheiner J et al., 2008, Genetic variants in FKBP5 affecting response to antidepressant drug treatment., Pharmacogenomics
    Papiol S et al., 2007, Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment., J Affect Disord
    Binder EB et al., 2004, Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment., Nat Genet
    Antypa N et al., 2014, Genomewide interaction and enrichment analysis on antidepressant response., Psychol Med
    Tsai SJ et al., 2008, Glycogen synthase kinase-3beta gene is associated with antidepressant treatment response in Chinese major depressive disorder., Pharmacogenomics J
    Garriock HA et al., 2010, A genomewide association study of citalopram response in major depressive disorder., Biol Psychiatry
    Rotberg B et al., 2013, Additive effects of 5-HTTLPR (serotonin transporter) and tryptophan hydroxylase 2 G-703T gene polymorphisms on the clinical response to citalopram among children and adolescents with depression and anxiety disorders., J Child Adolesc Psychopharmacol
    Casamassima F et al., 2010, Phenotypic effects of a bipolar liability gene among individuals with major depressive disorder., Am J Med Genet B Neuropsychiatr Genet
    Gupta M et al., 2016, TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics., Mol Psychiatry
    Breitenstein B et al., 2016, Association of ABCB1 gene variants, plasma antidepressant concentration, and treatment response: Results from a randomized clinical study., J Psychiatr Res
    Huang X et al., 2013, ABCB6, ABCB1 and ABCG1 genetic polymorphisms and antidepressant response of SSRIs in Chinese depressive patients., Pharmacogenomics
    de Klerk OL et al., 2013, ABCB1 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large sample of Dutch cases with major depressive disorder., Pharmacogenomics J
    Uhr M et al., 2008, Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression., Neuron
    Adkins DE et al., 2012, Genome-wide pharmacogenomic study of citalopram-induced side effects in STAR*D., Transl Psychiatry
    Wang P et al., 2018, Association of DNA methylation in BDNF with escitalopram treatment response in depressed Chinese Han patients., Eur J Clin Pharmacol
    Murphy GM Jr et al., 2013, BDNF and CREB1 genetic variants interact to affect antidepressant treatment outcomes in geriatric depression., Pharmacogenet Genomics
    Musil R et al., 2013, No influence of brain-derived neurotrophic factor (BDNF) polymorphisms on treatment response in a naturalistic sample of patients with major depression., Eur Arch Psychiatry Clin Neurosci
    Yoshimura R et al., 2011, The brain-derived neurotrophic factor (BDNF) polymorphism Val66Met is associated with neither serum BDNF level nor response to selective serotonin reuptake inhibitors in depressed Japanese patients., Prog Neuropsychopharmacol Biol Psychiatry
    Zou YF et al., 2010, Association of brain-derived neurotrophic factor genetic Val66Met polymorphism with severity of depression, efficacy of fluoxetine and its side effects in Chinese major depressive patients., Neuropsychobiology
    Domschke K et al., 2010, Brain-derived neurotrophic factor ( BDNF) gene: no major impact on antidepressant treatment response., Int J Neuropsychopharmacol
    Demirbugen Oz M et al., 2018, The relationship between the serotonin 2A receptor gene -1438A/G and 102T/C polymorphisms and citalopram/sertraline-induced nausea in major depressed patients., Hum Psychopharmacol
    Smith RM et al., 2013, Multiple regulatory variants modulate expression of 5-hydroxytryptamine 2A receptors in human cortex., Biol Psychiatry
    Paddock S et al., 2007, Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort., Am J Psychiatry
    Lin E et al., 2015, Genome-wide association studies in pharmacogenomics of antidepressants., Pharmacogenomics
    Ji Y et al., 2011, Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics., Clin Pharmacol Ther
    Amitai M et al., 2016, Pharmacogenetics of citalopram-related side effects in children with depression and/or anxiety disorders., J Neural Transm (Vienna)
  • CITALOPRAM   METTL21A

    Interaction Score: 5.62

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20643483 17548750


    Sources:
    PharmGKB

  • CITALOPRAM   GLDC

    Interaction Score: 1.87

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21107318


    Sources:
    PharmGKB

  • CITALOPRAM   TSPAN5

    Interaction Score: 1.87

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26903268


    Sources:
    PharmGKB

  • CITALOPRAM   COL26A1

    Interaction Score: 1.87

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22760553


    Sources:
    PharmGKB

  • CITALOPRAM   ERICH3

    Interaction Score: 1.87

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26903268


    Sources:
    PharmGKB

  • CITALOPRAM   PAPLN

    Interaction Score: 1.87

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • CITALOPRAM   NEDD4L

    Interaction Score: 1.87

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23809733


    Sources:
    PharmGKB

  • CITALOPRAM   CREB1

    Interaction Score: 1.41

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20643483 17548750


    Sources:
    PharmGKB

  • CITALOPRAM   CRHR2

    Interaction Score: 1.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17467808


    Sources:
    PharmGKB

  • CITALOPRAM   RORA

    Interaction Score: 1.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19846067


    Sources:
    PharmGKB

  • CITALOPRAM   FKBP5

    Interaction Score: 1.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23733030 21449676 20709156 19676097 18597649 17467808 15565110


    Sources:
    PharmGKB

  • CITALOPRAM   RFK

    Interaction Score: 0.94

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • CITALOPRAM   REEP5

    Interaction Score: 0.94

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22795047


    Sources:
    PharmGKB

  • CITALOPRAM   SRP19

    Interaction Score: 0.94

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22795047


    Sources:
    PharmGKB

  • CITALOPRAM   DTNBP1

    Interaction Score: 0.94

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19065121


    Sources:
    PharmGKB

  • CITALOPRAM   TPH1

    Interaction Score: 0.83

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23733030 23221997 19590397


    Sources:
    PharmGKB

  • CITALOPRAM   TPH2

    Interaction Score: 0.75

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23510446


    Sources:
    PharmGKB

  • CITALOPRAM   SLC6A4

    Interaction Score: 0.54

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name -

    PMIDs:
    19500602 7548008 15955412 11180498 17916059 9537821 10546982 10063489 11300876 19616061 10188639 27049939 21546862


    Sources:
    TdgClinicalTrial TEND

  • CITALOPRAM   IL11

    Interaction Score: 0.54

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25916525


    Sources:
    PharmGKB

  • CITALOPRAM   BDNF

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29748862 23733030 23619509 22965830 21338649 20016225 19236730


    Sources:
    PharmGKB

  • CITALOPRAM   GRIA3

    Interaction Score: 0.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17898344


    Sources:
    PharmGKB

  • CITALOPRAM   SERPINE1

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18794724


    Sources:
    PharmGKB

  • CITALOPRAM   GRK5

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • CITALOPRAM   CACNA1C

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19388002


    Sources:
    PharmGKB

  • CITALOPRAM   HTR1B

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27324805


    Sources:
    PharmGKB

  • CITALOPRAM   HTR2A

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30221791 23158458 19590397 17671280


    Sources:
    PharmGKB

  • CITALOPRAM   GSK3B

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18195729


    Sources:
    PharmGKB

  • CITALOPRAM   ABCB1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26704739 24192121 22641028 21546862 18215618


    Sources:
    PharmGKB

  • CITALOPRAM   CYP3A5

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • CITALOPRAM   CYP3A4

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21546862


    Sources:
    PharmGKB

  • CITALOPRAM   CYP2C19

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    FDA

  • CITALOPRAM   CYP2D6

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    FDA

  • CITALOPRAM   EHMT2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEND: CITALOPRAM

    • Version: 01-August-2011

    Alternate Names:
    CITALOPRAM Primary Drug Name

    Drug Info:
    Year of Approval 1998
    Drug Class antidepressive agents, second-generation

    Publications:

  • TdgClinicalTrial: CITALOPRAM

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Antidepressive Agents, Second-Generation
    Drug Class small molecule
    FDA Approval 1998

    Publications:

  • PharmGKB: citalopram

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Laje G et al., 2007, Genetic markers of suicidal ideation emerging during citalopram treatment of major depression., Am J Psychiatry
    Tsai SJ et al., 2008, Plasminogen activator inhibitor-1 gene is associated with major depression and antidepressant treatment response., Pharmacogenet Genomics
    Rotberg B et al., 2013, Additive effects of 5-HTTLPR (serotonin transporter) and tryptophan hydroxylase 2 G-703T gene polymorphisms on the clinical response to citalopram among children and adolescents with depression and anxiety disorders., J Child Adolesc Psychopharmacol

  • TTD: Citalopram

    • Version: 2020.06.01

    Alternate Names:
    D0Y5DO TTD Drug ID

    Drug Info:

    Publications:

  • DTC: CITALOPRAM

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL549 ChEMBL Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL549

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Citalopram

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21